Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Omnicell, Inc. (OMCL - Analyst Report) has forged a new agreement with Bupa Care Homes to take over the entire outstanding share capital of SurgiChem Limited, a wholly-owned subsidiary of Bupa. The cash transaction is valued at $19.6 million, subject to certain adjustments and clearance from the UK competition authorities.

SurgiChem, based in Stockport, U.K. with 21 employees, is a provider of medication adherence packaging systems and solutions to the UK community and home care markets.

Omnicell, a leading provider of medication and supply management solutions to healthcare systems, serves a niche industry but faces stiff competition in the market. However, it expects to shield itself by pursuing a three-pronged strategy of domestic expansion, selective acquisitions and targeted international expansion.

The MTS Medication Technologies subsidiary has consistently yielded encouraging results for Omnicell. This has prompted the company to further penetrate the non-acute care market on the back of strategic investments.

Medication non-adherence is gradually emerging as a potent issue in public health care systems. The market holds underlying opportunities as both healthcare systems and community pharmacies are of the view that medication adherence is a key to delivering better clinical outcomes and financial results. Poor adherence increases chances of medical complications, to the extent of death and morbidity. It can shoot healthcare expenses up by as high as $290 billion annually and cause 125,000 deaths in a year.

The present scenario of the market, has encouraged Omnicell to undertake such an acquisition. It is expected to set a platform for the company to provide comprehensive solutions, as its MTS brand of products and the SurgiChem products complement each other well in addressing the medical adherence problem in the U.K. This integration is expected to widen the range of products and services across the UK medication adherence packaging market.

The acquisition will widen Omnicell’s scope within a niche segment by increasing penetration levels in the overseas market. We believe that such selective buyouts, particularly outside U.S., will help Omnicell generate impressive revenues and ease the pressure on margin expansion in the long run.

Currently, Omnicell carries a Zacks Rank #4 (Sell). Investors interested in the industry can look at stocks like Align Technology Inc. (ALGN - Analyst Report) sports a Zacks Rank #1 (Strong Buy) while Cardinal Health, Inc. (CAH - Analyst Report) and Affymetrix Inc. (AFFX - Analyst Report) carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +6.05%
QUESTCOR PHA QCOR 80.07 +2.47%
VIPSHOP HOLD VIPS 156.35 +1.82%
ENLINK MIDST ENLC 36.29 +1.60%
BNC BANCORP BNCN 17.33 +1.58%